155 related articles for article (PubMed ID: 28324747)
1. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Lee JC; Kim JW; Ahn S; Kim HW; Lee J; Kim YH; Paik KH; Kim J; Hwang JH
Eur J Cancer; 2017 May; 76():125-133. PubMed ID: 28324747
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
3. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
[TBL] [Abstract][Full Text] [Related]
6. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Chllamma MK; Cook N; Dhani NC; Giby K; Dodd A; Wang L; Hedley DW; Moore MJ; Knox JJ
Br J Cancer; 2016 Sep; 115(6):649-54. PubMed ID: 27467054
[TBL] [Abstract][Full Text] [Related]
8. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Mahaseth H; Brutcher E; Kauh J; Hawk N; Kim S; Chen Z; Kooby DA; Maithel SK; Landry J; El-Rayes BF
Pancreas; 2013 Nov; 42(8):1311-5. PubMed ID: 24152956
[TBL] [Abstract][Full Text] [Related]
9. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
[TBL] [Abstract][Full Text] [Related]
10. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.
Todaka A; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Nakamori S; Yachi Y; Henmi T; Kobayashi M; Boku N; Mori K; Fukutomi A
Pancreas; 2018; 47(5):631-636. PubMed ID: 29683973
[TBL] [Abstract][Full Text] [Related]
11. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
Byrne JD; Jajja MR; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2200-5. PubMed ID: 26858448
[TBL] [Abstract][Full Text] [Related]
12. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature.
Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R
Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312
[TBL] [Abstract][Full Text] [Related]
13. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
Peddi PF; Lubner S; McWilliams R; Tan BR; Picus J; Sorscher SM; Suresh R; Lockhart AC; Wang J; Menias C; Gao F; Linehan D; Wang-Gillam A
JOP; 2012 Sep; 13(5):497-501. PubMed ID: 22964956
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis.
Baldini C; Escande A; Bouché O; El Hajbi F; Volet J; Bourgeois V; Renaut Vantroys T; Ploquin A; Desauw C; Hebbar M
Pancreatology; 2017; 17(1):146-149. PubMed ID: 28040425
[TBL] [Abstract][Full Text] [Related]
15. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
Kiba T; Okada Y; Kajiume S; Yamaguchi A
Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
[TBL] [Abstract][Full Text] [Related]
16. Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy.
Guion-Dusserre JF; Bertaut A; Ghiringhelli F; Vincent J; Quipourt V; Marilier S; Tharin Z; Bengrine-Lefevre L
World J Gastroenterol; 2016 Nov; 22(42):9378-9386. PubMed ID: 27895425
[TBL] [Abstract][Full Text] [Related]
17. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
Zahir MN; Jabbar AA
Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
[TBL] [Abstract][Full Text] [Related]
18. Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment.
Jung JH; Shin DW; Kim J; Lee JC; Hwang JH
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33120908
[TBL] [Abstract][Full Text] [Related]
19. [Primary Prophylactic Administration of Pegfilgrastim in FOLFIRINOX Therapy for Locally Advanced Pancreatic Carcinoma].
Ninomiya R; Nakazawa A; Miyata Y; Mitsui T; Komagome M; Maki A; Ozawa F; Beck Y
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1678-1680. PubMed ID: 28133096
[TBL] [Abstract][Full Text] [Related]
20. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
Pietrasz D; Marthey L; Wagner M; Blanc JF; Laurent C; Turrini O; Raoul JL; Terrebonne E; Hentic O; Trouilloud I; Coriat R; Regenet N; Innominato P; Taieb J; Cunha AS; Bachet JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1196-205. PubMed ID: 26271395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]